# NewAmsterdam Pharma Company N.V. (NAMS): MoatMap facts

As of 24 Oct 2026. Research data, not investment advice.

As of 24 Oct 2026, MoatMap's StockRank for NewAmsterdam Pharma Company N.V. (NAMS) is 10/100, ranked against 24,000+ stocks in 35 markets (Quality 30, Value 24, Momentum 29, each scored against its sector).

- StockRank: 10/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 30, Value 24, Momentum 29: each a 0-100 percentile within Healthcare.
- Position: #24,171 overall, #2,276 in Healthcare.
- Listing: United States, NGM; Healthcare / Biotechnology.
- Last close: 19.71 USD on 23 Oct 2026.
- Insider filings, last 180 days: directors bought USD 227K; directors sold USD 11.4M.

Source: https://moatmap.ai/stock/NAMS
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker